Evidence map›Paper›PMID 41162496›Full record

ArticleScientific reports2025

Innovative green niosomal piperlongumine as a novel topical treatment for dermatophytosis in guinea pigs model.

Iman Haghani, Abbas Raeisabadi, Javad Akhtari, Aylar Arbabi, Mahdi Abastabar, Mohamad Taghi Hedayati, Zahra Yahyazadeh, Fereshteh Talebpour Amiri, Seyyed Mohammad Hassan Hashemi, Lotfollah Davoodi and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Iman HaghaniInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Abbas RaeisabadiInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Javad AkhtariDepartment of Medical Nanotechnology, Immunogenetics Research Center, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Aylar ArbabiInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mahdi AbastabarInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mohamad Taghi HedayatiInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Zahra YahyazadehInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Fereshteh Talebpour AmiriCellular and Molecular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Seyyed Mohammad Hassan HashemiFood Health Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Lotfollah DavoodiDepartment of Infectious and Tropical Diseases, Research Center for Microbial Resistance and Communicable Diseases, Mazandaran University of Medical Sciences, Sari, Iran.
Yashar Hossein NezhadStudent Research Committee, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Ali Siahposht-KhachakiDepartment of Physiology and Pharmacology, Mazandaran University of Medical Sciences, Ramsar International Branch, Sari, Iran.
Azadeh BandeganiInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Seyyed Mobin RahimniaDepartment of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. mobin.rahimnia@yahoo.com.
Hamid BadaliDepartment of Molecular Microbiology and Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX, USA. hamid.badali@utsa.edu.

Funding

Mazandaran University of Medical Sciences 15210
6 · The paper itself

Abstract

Dermatophytosis is a common superficial fungal infection that affects many people worldwide. Although various species of dermatophytes respond to common antifungal drugs, the recently identified Trichophyton indotineae isolates have exhibited significant terbinafine resistance due to mutations in the Squalene Epoxidase (SQLE) gene. Piperlongumine (PL), a natural alkaloid that stimulates ROS production and inhibits some crucial enzymes, has a good capacity to treat these fungal infections. As part of nanotechnology, niosomes can increase the success of the drug by targeting the affected areas. This study investigates the effectiveness of PL niosomal gel 1% in an infected animal model with T. indotineae, providing important insights for infection treatment. Thirty guinea pigs empirically infected with T. indotineae were divided into five groups (e.g., untreated control, treated groups with terbinafine 1%, niosome, PL gel 1%, and PL niosomal gel 1%) and subsequently scored both clinically and mycologically until the 38th day of inoculation. On the 38th day of the study, histological evaluation was performed. In contrast to the terbinafine group, which demonstrated no efficacy (P < 0.05), the 1% PL niosomal gel significantly decreased mycological and clinical lesion scores, leading to complete mycological cure (negative fungal cultures) by day 28. Moreover, histopathological analysis confirmed that this compound reduced epidermal thickness, fungal burden, and inflammation. However, it should be noted that the difference in recovery rate of pigs with PL gel 1% and PL niosomal gel 1% was not statistically significant (p = 0.6). Treatment of T. indotineae dermatophytosis using PL niosomal gel is a safer and more effective alternative to conventional topical and oral antifungal therapies. However, further studies are warranted to correlate these findings with clinical outcomes.

Indexed as

Antifungal AgentsDioxolanesTineaAdministration, TopicalAnimalsDisease Models, AnimalGuinea PigsLiposomesPiperidonesSkinTerbinafineTrichophytonAntifungal AgentsDioxolanesLiposomesPiperidonespiperlongumineTerbinafineDermatophytosisNiosomal gelPiperlongumineTrichophyton indotineae

Identifiers

PMID41162496
PMCPMC12572209

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.